TrialNature communications2021

Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.

Si-Yang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.